Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $126545.0.

  • BioRestorative Therapies' Change in Accured Expenses fell 4606.27% to $126545.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$74767.0, marking a year-over-year decrease of 15609.56%. This contributed to the annual value of $32799.0 for FY2024, which is 9436.07% down from last year.
  • Per BioRestorative Therapies' latest filing, its Change in Accured Expenses stood at $126545.0 for Q3 2025, which was down 4606.27% from $203315.0 recorded in Q2 2025.
  • BioRestorative Therapies' 5-year Change in Accured Expenses high stood at $284658.0 for Q4 2021, and its period low was -$466875.0 during Q1 2025.
  • Over the past 5 years, BioRestorative Therapies' median Change in Accured Expenses value was $138525.0 (recorded in 2024), while the average stood at $67640.8.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 162639000.0% in 2023, then crashed by 49119.35% in 2024.
  • BioRestorative Therapies' Change in Accured Expenses (Quarter) stood at $284658.0 in 2021, then tumbled by 94.58% to $15423.0 in 2022, then surged by 955.14% to $162734.0 in 2023, then crashed by 61.75% to $62248.0 in 2024, then soared by 103.29% to $126545.0 in 2025.
  • Its Change in Accured Expenses was $126545.0 in Q3 2025, compared to $203315.0 in Q2 2025 and -$466875.0 in Q1 2025.